GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cocrystal Pharma Inc (NAS:COCP) » Definitions » Effective Interest Rate on Debt %

Cocrystal Pharma (Cocrystal Pharma) Effective Interest Rate on Debt % : 0.00% (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Cocrystal Pharma Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Cocrystal Pharma's annualized positive value of Interest Expense for the quarter that ended in Mar. 2024 was $0.00 Mil. Cocrystal Pharma's average total debt for the quarter that ended in Mar. 2024 was $1.84 Mil. Therefore, Cocrystal Pharma's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 was 0.00%.


Cocrystal Pharma Effective Interest Rate on Debt % Historical Data

The historical data trend for Cocrystal Pharma's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cocrystal Pharma Effective Interest Rate on Debt % Chart

Cocrystal Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.31 1.13 0.71 0.48 -

Cocrystal Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cocrystal Pharma's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Cocrystal Pharma's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cocrystal Pharma's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cocrystal Pharma's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Cocrystal Pharma's Effective Interest Rate on Debt % falls into.



Cocrystal Pharma Effective Interest Rate on Debt % Calculation

Cocrystal Pharma's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2022 )+Total Debt  (A: Dec. 2023 ))/ count )
=-1  *  0/( (0.297+1.853)/ 2 )
=-1  *  0/1.075
=0.00 %

where

Total Debt  (A: Dec. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.057 + 0.24
=0.297

Total Debt  (A: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=1.613 + 0.24
=1.853

Cocrystal Pharma's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Dec. 2023 )+Total Debt  (Q: Mar. 2024 ))/ count )
=-1  *  0/( (1.853+1.822)/ 2 )
=-1  *  0/1.8375
=0.00 %

where

Total Debt  (Q: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=1.613 + 0.24
=1.853

Total Debt  (Q: Mar. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=1.582 + 0.24
=1.822

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Cocrystal Pharma  (NAS:COCP) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Cocrystal Pharma Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Cocrystal Pharma's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cocrystal Pharma (Cocrystal Pharma) Business Description

Industry
Traded in Other Exchanges
Address
19805 North Creek Parkway, Bothell, WA, USA, 98011
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
Executives
Fred Hassan director C/O CARET GROUP,, 1100 HOLLAND DR., BOCA RATON FL 33487
Frost Phillip Md Et Al director, 10 percent owner 4400 BISCAYNE BLVD, MIAMI FL 33137-3227
Pfenniger Richard C Jr director 4400 BISCAYNE BLVD., MIAMI FL 33137
Raymond F Schinazi director, 10 percent owner 1860 MONTREAL ROAD, TUCKER GA 30084
Anthony J Japour director 19805 N. CREEK PARKWAY, BOTHELL WA 98011
Todd R. Brady director 19805 N. CREEK PARKWAY, BOTHELL WA 98011
James Joseph Martin officer: Interim CFO 4400 BISCAYNE BLVD, SUITE # 670, MIAMI FL 33157
Curtis Dale officer: INTERIM CFO 1860 MONTREAL ROAD, TUCKER GA 30084
Douglas L Mayers officer: CHIEF MEDICAL OFFICER C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02139
Walt Addison Linscott officer: GENERAL COUNSEL AND SECRETARY 1860 MONTREAL ROAD, TUCKER GA 30084
Jeffrey A Meckler director 740 BROADWAY, 9TH FLOOR, NEW YORK NY 10003
David S Block director
Hsiao Jane Ph D director 4400 BISCAYNE BLVD, MIAMI FL 33137
Steven D Rubin director OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Roger D. Kornberg director 345 WALSH ROAD, ATHERTON CA 94027

Cocrystal Pharma (Cocrystal Pharma) Headlines

From GuruFocus

Cocrystal Pharma Announces Participation in Virtual Investor Events

By Stock market mentor Stock market mentor 01-26-2023